These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 22184649

  • 1. Use of palivizumab in primary practice.
    Perrin KM, Bégué RE.
    Pediatrics; 2012 Jan; 129(1):55-61. PubMed ID: 22184649
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis.
    Mansbach J, Kunz S, Acholonu U, Clark S, Camargo CA.
    Pediatr Emerg Care; 2007 Jun; 23(6):362-7. PubMed ID: 17572518
    [Abstract] [Full Text] [Related]

  • 3. The effect of an interventional program on adherence to the american academy of pediatrics guidelines for palivizumab prophylaxis.
    Afghani B, Ngo T, Leu SY, Wu FL, Cecilio M, Aron-Johnson P, Zeitany R, Sills J, Amin A.
    Pediatr Infect Dis J; 2006 Nov; 25(11):1019-24. PubMed ID: 17072124
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
    Weiner LB, Masaquel AS, Polak MJ, Mahadevia PJ.
    J Med Econ; 2012 Nov; 15(5):997-1018. PubMed ID: 22435648
    [Abstract] [Full Text] [Related]

  • 5. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
    Chadha AD, Bao W, Holloway J, Mann J, Rye AK, Brown DE.
    South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
    [Abstract] [Full Text] [Related]

  • 6. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M, Nerwen C, Boron M, Cohen A, VanVeldhuisen P, Harrington M, Groothuis J, Palivizumab Outcomes Registry Group.
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [Abstract] [Full Text] [Related]

  • 7. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.
    Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB.
    J Med Econ; 2012 Oct; 15(5):987-96. PubMed ID: 22574798
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Rate of palivizumab administration in accordance with current recommendations among hospitalized children.
    Moynihan JA, Kim TY, Young T, Checchia PA.
    J Pediatr Health Care; 2004 Dec; 18(5):224-7. PubMed ID: 15337916
    [Abstract] [Full Text] [Related]

  • 16. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients.
    Teusink-Cross A, Davies SM, Danziger-Isakov L, El-Bietar J, Grimley MS.
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1904-1906. PubMed ID: 27422147
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program.
    Lundeen K, Pfeiffenberger T, Jacobson Vann J, O'Brien T, Sampson C, Wegner S.
    J Manag Care Pharm; 2013 Mar; 19(2):115-24. PubMed ID: 23461427
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.